- Home
- / Kala Pharmaceuticals
- / Financials
Header placeholder lorem ipsum dolor sit amet, consectetur adipiscing elit.
Kala Pharmaceuticals financials data including stock price, CreditSafe score, income statement, balance sheet, and cash flow.
Stock Price
$7.2
2024-10-29
Market Capitalization
$39.4 M
2024-10-29
Revenue
$3.9 M
FY, 2022
CreditSafe Score
?
Score changed on Jun 23, 2026
Premium Content only available in Craft’s Intelligence Portal
View 30+ financial ratio metrics including price-to-earnings ratio, debt-to-assets ratio, gross profit margin, and more.
Financial ratio metrics help evaluate the financial strength of a company, and help raise red flags that can indicate potential risk, fulfillment challenges, or even possible bankruptcy.
Learn moreFinancial Statements
| USD | FY, 2015 | FY, 2016 | FY, 2017 | FY, 2018 | FY, 2019 | FY, 2020 | FY, 2021 | FY, 2022 | FY, 2023 | FY, 2024 | FY, 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 45.0K | 6.1M | 6.4M | 11.2M | 3.9M | ||||||
| General and administrative expense | 4.6M | 7.6M | 10.9M | 35.4M | 65.0M | 81.1M | 105.1M | 65.0M | 20.6M | 18.3M | 23.6M |
| Operating expense total | 16.0M | 32.7M | 37.5M | 62.7M | 86.2M | 91.3M | 104.2M | 82.7M | 39.2M | 40.4M | 42.4M |
| EBIT | (15.9M) | (32.7M) | (39.9M) | (64.7M) | (88.2M) | (96.2M) | (130.2M) | (81.7M) | (39.7M) | (41.0M) | (39.2M) |
| EBIT margin, % | -35435.6% | -1452.5% | -1512.6% | -1158.8% | -2099.3% | ||||||
| Interest income | 147.0K | 527.0K | 1.7M | 2.4M | 493.0K | 104.0K | 664.0K | 2.7M | 2.1M | 1.1M | |
| Interest expense | 604.0K | 767.0K | 1.0M | 3.3M | 8.5M | 8.6M | 8.4M | 7.3M | 5.8M | 4.6M | |
| Net Income | (16.7M) | (33.2M) | (42.2M) | (66.7M) | (94.3M) | (104.3M) | (142.6M) | (44.8M) | (42.2M) | (38.5M) | (27.0M) |
| EPS | (2.2) | (29.5) | (17.3) | (10.1) | (3.3) |